8-K: ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity of PMN310 Antibody for Alzheimer's Treatment

ProMIS Neurosciences announced the publication of a study demonstrating that their antibody, PMN310, exhibits high selectivity for toxic amyloid-beta oligomers, potentially improving efficacy and reducing side effects in Alzheimer's treatment.

Summary

• ProMIS Neurosciences has published a study in bioRxiv detailing the binding profile of various amyloid-beta (Aβ)-directed antibodies.
• The study compared the antibodies' binding to monomers, soluble oligomers, and insoluble Aβ fibrils.
• Results indicate that selectivity for soluble toxic Aβ oligomers may be a key factor in clinical efficacy.
• PMN310, ProMIS's novel monoclonal antibody for Alzheimer's disease (AD), showed the greatest degree of oligomer selectivity.
• PMN310 also demonstrated a high resistance to monomer competition, unlike other antibodies tested.
• Importantly, PMN310 avoided binding to plaque and vascular deposits of Aβ, potentially reducing the risk of brain edema (ARIA-E) and microhemorrhages (ARIA-H).
• A murine version of PMN310, dosed at 800 mg/kg weekly for 26 weeks in a mouse model of AD, did not cause any detectable brain hemorrhages.
• The company anticipates top-line data from their Phase 1a study in mid-2024 and plans to advance to a Phase 1b multiple ascending dose study in AD patients.

Sentiment

Score: 7

Explanation: The document presents positive preclinical data and a clear path forward for PMN310, but also acknowledges the risks associated with clinical development and the company's financial situation. The potential for a safer and more effective Alzheimer's treatment is promising, but the risks temper the overall sentiment.

Positives

• PMN310 exhibits a high degree of selectivity for toxic Aβ oligomers, which may lead to improved clinical efficacy.
• The antibody's resistance to monomer competition suggests it can maintain its effectiveness in the presence of other Aβ forms.
• The avoidance of plaque and vascular binding may reduce the risk of serious side effects like brain edema and microhemorrhages.
• Preclinical studies in mice showed no detectable brain hemorrhages at high doses, supporting the safety profile of PMN310.
• The company is progressing towards a Phase 1b study in AD patients, indicating advancement in clinical development.

Negatives

• The study is based on preclinical data and early clinical trials, which may not be fully predictive of future results.
• The company has an accumulated deficit and expects continued losses, raising concerns about its financial sustainability.
• The company's ability to fund its operations and continue as a going concern is a risk factor.

Risks

• The results of nonclinical studies and early clinical trials may not be predictive of future results with PMN310.
• The company's ability to fund its operations and continue as a going concern is uncertain.
• The company has an accumulated deficit and expects continued losses.
• There are risks associated with the clinical development of PMN310, including the possibility of unexpected side effects or lack of efficacy.
• The company's financial results may be materially different from those anticipated.

Future Outlook

The company anticipates top-line data from their Phase 1a study in mid-2024 and plans to advance to a Phase 1b multiple ascending dose study in AD patients.

Management Comments

• Neil Warma, Chief Executive Officer of ProMIS Neurosciences, stated that the data highlights PMN310's high degree of selectivity for toxic Aβ oligomers and its differentiation from other Aβ-directed antibodies.
• Mr. Warma also mentioned that PMN310's ability to avoid both monomer and plaque binding has the potential to improve efficacy and reduce the risk of amyloid-related imaging abnormalities (ARIA).

Industry Context

This announcement is relevant to the broader industry trend of developing targeted antibody therapies for neurodegenerative diseases, particularly Alzheimer's. The focus on oligomer selectivity and reducing side effects like ARIA is a key area of research and development in this field.

Comparison to Industry Standards

• The study compares PMN310 to other Aβ-directed antibodies that have been tested clinically for Alzheimer's, highlighting PMN310's superior oligomer selectivity and reduced plaque binding.
• Other companies like Biogen and Eisai have developed plaque-binding antibodies, such as Aduhelm and Leqembi, which have shown efficacy but also carry risks of ARIA.
• PMN310's ability to avoid plaque binding could position it as a safer alternative with potentially improved efficacy due to its focus on toxic oligomers.
• The results suggest that PMN310 may address some of the limitations of existing therapies by targeting a different form of Aβ and reducing side effects.

Stakeholder Impact

• Shareholders may view the positive study results as a positive development for the company's prospects.
• Patients with Alzheimer's disease and their families may see hope in the potential for a safer and more effective treatment.
• Employees may be encouraged by the progress of the company's lead product.
• The scientific community may be interested in the study's findings and their implications for Alzheimer's research.

Next Steps

• The company anticipates top-line data readout for the Phase 1a study in mid-2024.
• The company plans to advance PMN310 into a Phase 1b multiple ascending dose study in AD patients.

Key Dates

Keywords

PMN310, Alzheimer's disease, amyloid-beta, oligomers, antibody, neurodegenerative diseases, clinical trials, ARIA, monoclonal antibody, biotechnology